Interní Med. 2007; 9(6): 273-275

Treatment of hypertension within the scope of stroke prevention

MUDr. Jiří Krupička Ph.D
Kardiochirurgické oddělení Nemocnice Na Homolce, Praha

Hypertension (both systolic and diastolic blood pressure – SBP, resp. DBP) has a direct relation to prevalence of stroke. By influencing hypertension we can prevent a stroke in a much larger scale than by a modification of other risk factors. The treatment of hypertension belongs to basic steps in primary or secondary prevention. Some clinical studies show that certain groups of medications may prevent a stroke in a larger scale than other groups of medications. The article attempts to summarize recent findings.

Keywords: hypertension, stroke, combination treatment, modern preparations

Published: November 9, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krupička J. Treatment of hypertension within the scope of stroke prevention. Interní Med. 2007;9(6):273-275.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cífková R. Arterial hypertension as a public health issue in the Czech Republic. Blood Press Suppl. 2005; 2: 25-8. Go to original source... Go to PubMed...
    2. Cohn JN, Neutel J, Houston M, et al. Early improvements in vascular compliance following coadministration of amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia. The Avalon Arterial Wall Compliance (AWC) trial. Program and abstracts from the 20th Annual Scientific Meeting of the American Society of Hypertension; May 14-18,2005; San Francisco, California. Late Breaking Clinical Trials.
    3. Dahlöf B, Sever PS, Poulter NR, for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
    4. Davis TM, Millens H, Stratten JM, et al. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med. 1999; 159: 1097-1103. Go to original source... Go to PubMed...
    5. Diener HC. NSA guidelines for management of transient ischaemic attacks. Lancet Neurol. 2006; 5: 996-997. Go to original source... Go to PubMed...
    6. Esposti LD, Di Martino M, Saragoni S, et al. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens 2004; 6: 76-84. Go to original source... Go to PubMed...
    7. Fagan TC, Sowers JR. Type 2 diabetes mellitus: greater cardiovascular risks and greater benefits of therapy. Arch Intern Med. 1999; 159 (10): 1033-1034. Go to original source... Go to PubMed...
    8. Fagard R. Long-term outcome results of the Systolic Hypertension in Europe trial (Syst-Eur). ESC Congress 2003, August 30-September 3, 2003, Vienna, Austria. Clinical Trial Update III Hypertension/Prevention, Presentation 3701.
    9. Flack J, Houston M, Neutel J, et al. Efficacy and safety of atorvastatin plus amlodipine versus either agent alone in patients with concomitant dyslipidemia and hypertension: the AVALON study. Program and abstracts from Hypertension 2004 - 20th scientific meeting of the International Society of Hypertension; February 15-19, 2004; S. Paulo, Brazil. J Hypertens. 2004; 22 (suppl I): 12S. Abstract OP 036. Go to original source...
    10. Gorelick PB. Stroke prevention therapy beyond antithrombotics: Unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. An Invited Review. Stroke, 2002; 33: 862-875. Go to original source... Go to PubMed...
    11. Guidelines Committee.2003 European Society of Hypertesion - European Society of Cardiology guidelines for the managment of arterial hypertension. J Hypertesion 2003; 21: 1011-53. Go to original source... Go to PubMed...
    12. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial-HOT Study Group. Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
    13. Kannel WB, Wolf PA, Verter J, et al. Epidemiologic assessment of the role of blood pressure in stroke: The Framingham Study. JAMA 1970; 214: 301-310. Go to original source... Go to PubMed...
    14. Kannel WB, Wolf PA, Verter J, et al. Epidemiologic assessment of the role of blood pressure in stroke: The Framingham Study. 1970. JAMA. 1996; 276: 1269-1278. Go to original source... Go to PubMed...
    15. Kaplan RC, Tirshwell DL, Longstreth WT Jr, et al. Blood pressure level and outcomes in adults aged 65 and older with prior ischemic stroke. J Am Geriatr Soc 2006; 54: 1309-1316. Go to original source... Go to PubMed...
    16. Neutel J, LaSalle J, Berman L, et al. Dual goal attainment with amlodipine/atorvastatin single pill in a broad range of patients: results from the GEMINI study. Am J Hypertens. 2004; 17 (5 Pt 2): 184A. Go to original source...
    17. NICE/BHS. Clinical guideline 34: hypertension: management of hypertension in adults in primary care: partial update. http://www.nice.org.uk/CG034 guidance (accessed June 28, 2006).
    18. Obisesan TO, Vargas CM, Gillum RF. Geographic variation in stroke risk in the United States: Region, urbanization, and hypertension in the Third National Health and Nutrition Examination Survey. Stroke 2000; 31: 19-25. Go to original source... Go to PubMed...
    19. Parati G. Blood pressure variability: its measurement and significance in hypertension. J Hypertens Suppl 2005 Apr; 23 (1): S19-S25. Go to original source... Go to PubMed...
    20. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041. Go to original source... Go to PubMed...
    21. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913. Go to original source... Go to PubMed...
    22. Ravipati G, Aronow WS, Ahn C, et al. Reduction of myocardial infarction or stroke or all-cause mortality in patients with carotid arterial disease treated with statins. CHEST 2006; October 21-26, 2006; Salt Lake City, UT. Abstract 3651. Go to original source...
    23. Sacco RL. Reducing the risk of stroke in diabetes: what have we learned that is new? Diabetes Obes Metab. 2002; 4 (suppl 1): S27-S34. Go to original source... Go to PubMed...
    24. Staessen JA, Wang JH, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens.2003 Jun; 21 (6): 1055-1076. Go to original source... Go to PubMed...
    25. The CAFE Investigators, for the ASCOT Investigators. Differential impact of blood pressurelowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 2006; 113. Go to original source... Go to PubMed...
    26. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355: 459-559. Go to original source... Go to PubMed...
    27. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-1297. Go to original source... Go to PubMed...
    28. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The heart outcomes prevention evaluation study investigators. N Engl J Med 2000; 342: 145-153. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.